PerkinElmer’s New Western Lighting™ Ultra Kits Illuminate Western Blotting Detection for the Most Demanding Applications i

Global leader in reagent solutions enables highest confidence in detection of protein expression for the investigation of new drug candidates for critical disease states

ANAHEIM, Calif.--(BUSINESS WIRE)-- At FASEB 2010 in Anaheim, California today, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced the launch of its Western Lighting™ Ultra chemiluminescent substrate kit. Designed for demanding applications for measuring post-translational modifications of weakly expressed proteins, Western Lighting™ Ultra produces outstanding sensitivity, a wide dynamic range and stable signal for assured results in all areas of life sciences research. Additionally, the kit helps reduce the use of primary antibodies by tenfold, providing more information from smaller samples, for faster and more economical research outcomes.

The new Western Lighting offering advances PerkinElmer’s position in high confidence protein detection techniques for basic and applied life science research. This new kit facilitates pharmacological studies by overcoming challenges in the investigation of cell signaling pathways, many of which require measurement of protein expression over a very wide dynamic range.

“Life sciences researchers increasingly recognize a growing need for producing data through highly sensitive methods of detecting proteins of interest, under a variety of challenging experimental conditions. We’ve addressed these needs with the new Western Lighting Ultra detection kit. Researchers can now take advantage of a more stable signal and dynamic range that provides more accurate results,” said Martina Bielefeld-Sévigny, PhD, vice president and general manager, drug discovery and research reagent solutions, Bio-discovery, PerkinElmer. "Ultimately, this capability will benefit investigations of potential new drugs, providing deeper insights into their effectiveness against critical diseases."

The increased sensitivity and signal stability of the Western Lighting Ultra reagents kit enables scientists to produce robust results whether proteins are expressed at high or low levels, saving time and resources by minimizing the need for repeated experiments. This allows researchers to gain critical insight into the results that are needed to further research with the highest confidence in the results.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.8 billion in 2009 has around 8,800 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.



CONTACT:

PerkinElmer, Inc.
Kim McCrossen, 781-663-5871
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  Environment  Research  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.